Trader Note — 9846 total
Lunai Bioworks heads into tomorrow's Q3 earnings print with a genuinely charged setup: short interest has more than doubled in a week, borrowing costs remain historically extreme, and the company itself has gone to war…
RETO enters its May 19 earnings date with a dramatic short position collapse as its 4-to-1 reverse stock split — effective May 18 — dominates the narrative. The headline this week is the speed of the short unwind.…
NEXA enters the post-earnings period with a sharp weekly loss and a puzzling mismatch: short interest is building fast while the borrow market points to anything but a crowded short. The week's defining moment came…
Spero Therapeutics just reported Q1 2026 results after the close on May 13, and the headline numbers tell a split story: EPS of -$0.13 beat the -$0.18 estimate, but quarterly revenue collapsed to $258K from $5.9M a…
APi Group heads into its Q1 2026 earnings call on May 15 with two of its most senior figures having sold tens of millions in stock this week — a strikingly visible signal ahead of the company's biggest near-term…
TI heads into the mid-May session with two catalysts landing on the same morning — a Q1 earnings release showing 22% revenue growth and a cooperation agreement with Teck Resources to evaluate germanium recovery from…
Genprex, Inc. enters its Q1 2026 earnings print — released today after market — with short sellers having aggressively rebuilt positions over the past month, the stock already 28% lower, and a deeply oversold tape that…
MRMD just reported Q1 2026 results after the close on May 13, beating the revenue consensus estimate of $38.75M with $39.48M in sales. The earnings call follows on May 14. That puts the stock at an interesting juncture…
Eledon Pharmaceuticals approaches its May 19 Q1 earnings report with a notable shift in positioning: short sellers have been covering, the stock is up 26% in a month, and the borrow market remains undemanding — a setup…
TTD enters the back half of May having absorbed one of its worst post-earnings weeks in recent memory — down 14% on the week to $21.14, with a broad analyst target-cutting exercise following a Q1 miss that confirmed…
CRISPR Therapeutics enters mid-May with one of the most heavily shorted profiles in the gene-editing space — yet the lending market has loosened meaningfully from its April extremes, creating a tension at the heart of…
Bionano Genomics heads into the post-earnings session with a story that is harder to dismiss than its micro-cap price suggests — but short sellers have yet to be convinced. The company reported Q1 2026 earnings after…
Outlook Therapeutics heads into its fiscal Q2 earnings release tomorrow — May 14 — with short sellers having tripled their position in six weeks and the options market tilting heavily toward calls. Short interest has…
Insight Molecular Diagnostics heads into the aftermath of its Q1 earnings print with a rare convergence: short interest more than doubling in a month, options tilting to the most defensive reading in a year, and a…
QMOM, the Alpha Architect U.S. Quantitative Momentum ETF, heads into mid-May with a striking divergence: short interest nearly doubled over the past month while the borrow market remains exceptionally loose. The most…
Madison Square Garden Sports Corp. heads into this week with a quietly building short position and a freshly downgraded Citi rating — a pairing that deserves attention even as the stock holds near its year-to-date…
Presurance Holdings is a micro-cap insurance name that just dropped fresh quarterly numbers — and the setup heading into the week tells two competing stories at once. Q1 adjusted EPS came in at -$0.16, a meaningful…
vTv Therapeutics just reported Q1 2026 results that blew past every estimate on the Street, landing EPS of $1.65 against a consensus of -$0.10 and revenue of $36.8M against a $20M forecast — and the timing couldn't be…
Shopify enters the week after a bruising earnings reaction with short sellers rebuilding positions and the options market sending a contrarian signal — the two rarely point in opposite directions this clearly. The Q1…
Fluent, Inc. reported Q1 2026 results after the close on May 13 — a beat on adjusted EPS but a miss on revenue — arriving into a week where the stock had already shed 11.5% and short interest was quietly…
